Need to keep on prime of the science and politics driving biotech at this time? Enroll to get our biotech e-newsletter in your inbox.
Morning! Immediately, we see that the FDA is extending its evaluation interval for a number of myeloma drug Blenrep. We additionally see extra layoffs at a gene-editing firm, and listen to Alnylam’s CEO advocate for a brand new coverage with regards to Medicare worth negotiations.
The necessity-to-know this morning
- Roche reported second-quarter earnings.
- Rocket Prescribed drugs introduced a restructuring that can embrace layoffs affecting 30% of its workers. The corporate is decreasing its money burn by 25% to deal with gene therapies for cardiovascular circumstances. It would not pursue the approval of a gene remedy for Fanconi anemia.
FDA delays GSK’s Blenrep resolution once more
From my colleague Andrew Joseph: The watch for a Meals and Drug Administration approval resolution on GSK’s blood most cancers drug Blenrep goes to take a bit longer.
